These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15458371)

  • 21. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
    Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
    Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
    Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
    Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
    Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
    Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating DNA in plasma or serum.
    Anker P; Stroun M
    Medicina (B Aires); 2000; 60(5 Pt 2):699-702. PubMed ID: 11188885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
    Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
    J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapy for lung cancer: practice and promise.
    Vattemi E; Claudio PP
    Ann Ital Chir; 2004; 75(3):279-89. PubMed ID: 15605515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
    Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
    Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results.
    Digel W; Lübbert M
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):1-11. PubMed ID: 15886007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of genes involved in squamous cell carcinoma of the lung using synchronized data from DNA copy number and transcript expression profiling analysis.
    Lo KC; Stein LC; Panzarella JA; Cowell JK; Hawthorn L
    Lung Cancer; 2008 Mar; 59(3):315-31. PubMed ID: 18029052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular genetic tumor markers in non-small cell lung cancer.
    Oyama T; Osaki T; Baba T; Nagata Y; Mizukami M; So T; Nakata S; Ichiki Y; Uramoto H; Sugaya M; Yoshimatsu T; Morita M; Hanagiri T; Sugio K; Kawamoto T; Yasumoto K
    Anticancer Res; 2005; 25(2B):1193-6. PubMed ID: 15865065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Progress in oncogenes and anti-cancer genes in lung cancer].
    Guo X; Deng W; Huang S
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):267-9. PubMed ID: 8762477
    [No Abstract]   [Full Text] [Related]  

  • 32. The molecular biology of lung cancer: application to early detection and prevention.
    Sabichi AL; Birrer MJ
    Oncology (Williston Park); 1993 Jun; 7(6):19-26; discussion 31-2, 37. PubMed ID: 8318356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
    Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
    J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
    Gautschi O; Bigosch C; Huegli B; Jermann M; Marx A; Chassé E; Ratschiller D; Weder W; Joerger M; Betticher DC; Stahel RA; Ziegler A
    J Clin Oncol; 2004 Oct; 22(20):4157-64. PubMed ID: 15483026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early detection of lung cancer using serum RNA or DNA markers: ready for "prime time" or for validation?
    Bunn PJ
    J Clin Oncol; 2003 Nov; 21(21):3891-3. PubMed ID: 14507944
    [No Abstract]   [Full Text] [Related]  

  • 36. New approaches for biomarker discovery in lung cancer.
    Valle RP; Chavany C; Zhukov TA; Jendoubi M
    Expert Rev Mol Diagn; 2003 Jan; 3(1):55-67. PubMed ID: 12528364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogene and tumor-suppressor gene products as serum biomarkers in occupational-derived lung cancer.
    Helmig S; Schneider J
    Expert Rev Mol Diagn; 2007 Sep; 7(5):555-68. PubMed ID: 17892364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
    Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
    Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing.
    Chong IW; Chang MY; Sheu CC; Wang CY; Hwang JJ; Huang MS; Lin SR
    Oncol Rep; 2007 Jul; 18(1):17-24. PubMed ID: 17549340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer].
    Grote HJ
    Verh Dtsch Ges Pathol; 2006; 90():216-26. PubMed ID: 17867600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.